RLRelmada Therapeutics, Inc. RLMD · NASDAQ
$3.27 -0.61% (-$0.02)
- Market cap
- $350.9M
- Enterprise value
- $339.6M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -30.8%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.45
- Free float
- 77.5%
About the company
Relmada Therapeutics, Inc. (RLMD) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders and other neurologically focused health conditions. Their research and development programs are aimed at discovering and developing new drug therapies for mood disorders, pain, and other neurological diseases. Among their main products are drugs based on new pharmacological mechanisms, which have the potential to provide new therapeutic options for patients with these health conditions. Relmada Therapeutics, Inc. aims to bring innovative treatment approaches and improve the quality of life for patients suffering from neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Sergio Traversa
Employees
17
Headquarters
Coral Gables
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number